Market Trends of Lymphedema Treatment Industry
Compression Therapy Segment is Expected to Witness Significant Growth Over the Forecast Period
Compression therapy in lymphedema treatment involves applying pressure to the affected area using specialized garments, such as compression stockings or bandages. This pressure helps promote the movement of lymphatic fluid, reduce swelling, and support the tissues.
The growth of the compression therapy segment in the lymphedema treatment market can be attributed to various advantages offered by the use of compression therapy in the drainage of excess lymphatic fluid, advancements in compression garment technology, and a rising number of strategies performed by prominent players. For instance, according to the article published by the Wounds Australia Journal in February 2022, compression therapy is considered the gold standard treatment for lymphoedema as it significantly reduces limb volume in individuals with lymphoedema, with the effect commencing within hours of application of compression. As per the same source, compression therapy reduces pain and other symptoms, such as limb heaviness. Therefore, due to the various advantages offered by compression therapy and its acceptance as a gold standard for the treatment of lymphedema, it is set to drive the market growth during the forecast period.
Furthermore, the active participation of the prominent players in the launch of advanced compression therapy devices and a surging number of investments are projected further to enhance the segment growth during the study period. For instance, in February 2022, Koya Medical, a healthcare company, secured an investment of USD 26 million in series B funding to advance its portfolio of active compression therapies for lymphedema and venous disorders.
Therefore, factors such as various advantages offered by compression therapy and the active participation of prominent players in the launch of advanced compression therapy devices worldwide are set to drive the segment growth during the forecast period.
North America is Expected to Dominate the Lymphedema Treatment Market
The lymphedema treatment market in North America is expected to register significant growth during the forecast period owing to the rising cases of lymphedema across the United States, Canada, and Mexico and the increasing number of product launches.
The high prevalence of lymphedema in the United States and the high risk of the development of lymphedema among cancer survivors in the country are set to drive the market growth during the forecast period. For instance, according to the data published by the Lymphatic Education & Research Network in February 2022, an estimated 10 million people lived with lymphedema (LE) in the United States in 2022. As per the same source, approximately 30% of breast cancer survivors in the United States acquire debilitating LE. Similarly, as per the article published by the Canadian Medical Association (CMA) Journal in April 2022, breast cancer–related lymphedema (BCRL) is a lifelong condition affecting approximately 20% of Canadian women who undergo treatment for breast cancer.
Furthermore, the rising number of investments by government organizations in the region is also estimated to drive market growth during the forecast period. For instance, as per the article published by the National Institute of Health (NIH) in March 2023, the United States government invested around USD 12 million in lymphedema research in the country in 2023. Moreover, the rising number of product developments in the country is also projected to drive market growth during the forecast period. For instance, in October 2022, ImpediMed Limited announced the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare. The pilot program will consist of an initial rollout of five SOZO units to establish lymphedema screening services for breast cancer patients in centers across the United States. Upon completing the pilot program, GenesisCare will evaluate a staged expansion to additional sites in the United States.
Therefore, factors such as the high prevalence of lymphedema, the rising number of investments by government organizations, and the surging number of product launches are projected to accelerate market growth during the forecast period.
